

CENTER Ventures (4123.TT)


2026Q2 Highlights




NAV Per Share NT\$ 33.47
29 Portfolio Companies | 14 IPOs

Release Date: August 18, 2026
Source: Market Observation Post System (MOPS) / Official Press Release


Interest-bearing Debt & Equity




Revenue (NT\$m)



Summary Income Statement (NT\$m)



Equity Investments : Value by Market Cap (NT\$m)



Portfolio Highlights



1167.HK
Stake 10%
Market Cap : ~\$15.2Bn

- Completed first-patient dosing in China for the Phase IIa trial of BET inhibitor JAB-8263 in rheumatoid arthritis.
- Entered into a licensing collaboration with AstraZeneca for pan-KRAS inhibitor JAB-23E73; the US\$100 mn upfront payment has been recognized, with breakeven expected in 2026.



4726.TT
Stake 21%
Market Cap : ~\$5.3Bn

- 1H26 revenue reached NT\$400mn, YoY +23%.
- Completed EMA, PMDA, and TFDA inspections.
- FDA inspection is expected to be completed in 2H26.



2659.HK
Stake 12%
Market Cap : ~11.3Bn

- NMPA accepted the NDA for self-developed injectable KJ103, marking the first filing of its kind in China.
- NMPA accepted the CTA for self-developed recombinant ulinastatin BJ044, advancing the established therapy into recombinant development.